Falk Gastro Info 12/2020

Video course abdominal ultrasound

Examination of abdominal vessels – Aorta longitudinal, topography

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim. ©2019 Falk Foundation e.V., Freiburg. All rights reserved.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:


Nielsen HL et al, Gut. 2020;69(11):1952–8
Infectious cause of microscopic colitis: Results of a population-based cohort study in Denmark revealed a high risk of microscopic colitis following infection with Campylobacter concisus in stools, suggesting that C. concisus may be involved in the pathogenesis of this disease.

Link to text

BStevens TW et al, Lancet Gastroenterol Hepatol. 2020;5(10):900–7
Long-term follow-up of the LIR!C trial (laparoscopic ileocecal resection vs. infliximab for terminal ileitis in Crohn’s disease): Long-term analyses of patients enclosed in the LIR!C trial support the notion that laparoscopic ileocecal resection is a reasonable treatment option for ileocecal Crohn’s disease. A considerable proportion of patients who underwent surgery did not require additional Crohn’s disease-related medications or only primary prophylaxis of recurrence. In contrast, most of the patients treated with infliximab required long-term therapy with biologics or escalation of therapies and approx. half of the patients ultimately required surgery.

Link to text

Richards T et al, Lancet. 2020;396(10259):1353–61
HePreoperative intravenous iron to treat anemia before major abdominal surgery:: : Preoperative intravenous iron supplementation was not superior to placebo to reduce the need for blood transfusion or mortality when administered to patients with anemia 10–42 days before elective major abdominal surgery.

Link to text Liver Biliary Tracts

Natarajan Y et al, Hepatology. 2020;72(4):1242–52
Non-alcoholic fatty liver disease (NAFLD): A recent retrospective cohort study confirms that patients with hepatic steatosis and persistently normal alanine aminotransferase do not have an increased risk of liver cirrhosis and hepatocellular carcinoma. Thus, these patients probably do not require close monitoring for liver outcomes.

Link to text

Casey LC et al, Hepatology. 2020;72(4):1366–77
Acute liver failure in pregnancy: In a current database evaluation, approx. 2% of acute liver failure cases occurred during pregnancy. Pregnancy-associated liver diseases (acute fatty liver of pregnancy or HELLP syndrome with hemolysis, elevated liver enzymes and low platelets) caused only about half of the cases. Prognosis of acute liver failure in pregnancy is still poor: In the current analysis, 11 of 70 patients (16%) required liver transplantation and 8 patients (11%) died.

Link to text

Iavarone M et al, J Hepatol. 2020;73(5):1063–71
COVID-19 and cirrhosis: A recent retrospective study suggests that patients with cirrhosis and COVID-19 have about twice the mortality rate than patients with cirrhosis and bacterial infection or COVID-19 patients without cirrhosis.

Link to text Oesophagus Stomach Duodenum

Mather JF et al, Am J Gastroenterol. 2020;115(10):1617–23
Impact of histamine-2 receptor antagonists on clinical outcomes of patients with COVID-19: According to a retrospective analysis of 878 patients, famotidine use in hospitalized patients with COVID-19 was associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower serum markers for severe inflammation.

Link to text

Dellon ES et al, N Engl J Med. 2020;383(17):1624–34
Novel therapy for eosinophilic gastritis and duodenitis:: The anti-Siglec-8 antibody AK002 significantly reduced gastrointestinal eosinophils and clinical symptoms in a phase 2 trial.

Link to text

Lowe DA et al, JAMA Intern Med. 2020;180(11):1491–9
Effects of time-restricted eating on weight loss: Time-restricted eating, in the absence of other interventions, was not more effective in weight loss than conventional eating (3 structured meals throughout the day) in a randomized clinical trial involving 116 participants with overweight and obesity.

Link to text Pancreas

Xu J et al, Lancet Oncol. 2020;21(11):1489–99
PreTherapy of advanced pancreatic neuroendocrine tumors (NETs): The multikinase inhibitor surufatinib significantly improved progression-free survival and had an acceptable safety profile in patients with advanced pancreatic NETs in a Chinese phase 3 trial.

Link to text

Online Live Event


January 28 – 29, 2021






Current Falk literature:
Microscopic colitis
Collagenous and lymphocytic colitis

Author: A. Tromm

(28 pages)

PDF download